<div id="readability-page-1"><p>Marshall Wace LLP lifted its stake in shares of  Harrow, Inc. (NASDAQ:HROW - Free Report) by 31.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 564,876 shares of the company's stock after purchasing an additional 135,202 shares during the period. Marshall Wace LLP owned 1.54% of Harrow worth $17,251,000 as of its most recent SEC filing.</p><p>Other large investors have also made changes to their positions in the company. Quarry LP purchased a new position in  Harrow during the first quarter worth approximately $32,000.  State of Wyoming acquired a new stake in shares of  Harrow in the 1st quarter worth $97,000.  Strs Ohio acquired a new position in shares of  Harrow during the 1st quarter valued at about $149,000.  SJS Investment Consulting Inc. boosted its position in shares of  Harrow by 97.6% during the 2nd quarter. SJS Investment Consulting Inc. now owns 6,073 shares of the company's stock valued at $185,000 after acquiring an additional 3,000 shares during the last quarter.  Finally, Maridea Wealth Management LLC purchased a new stake in shares of  Harrow in the second quarter valued at about $202,000. 72.76% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Harrow Trading Up 1.9%</h2><p>HROW opened at $48.37 on Wednesday. Harrow, Inc. has a 52 week low of $20.85 and a 52 week high of $50.72. The company has a quick ratio of 2.52, a current ratio of 2.72 and a debt-to-equity ratio of 5.21. The business has a fifty day simple moving average of $40.10 and a 200-day simple moving average of $37.08. The firm has a market cap of $1.79 billion, a P/E ratio of -483.65 and a beta of 0.07. </p><p>Harrow (NASDAQ:HROW - Get Free Report) last posted its earnings results on Monday, November 10th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.11. The firm had revenue of $71.64 million for the quarter, compared to analyst estimates of $73.70 million. Harrow had a positive return on equity of 28.71% and a negative net margin of 1.99%. On average, equities analysts expect that  Harrow, Inc. will post -0.53 earnings per share for the current year. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several equities analysts have weighed in on HROW shares. B. Riley  reiterated a &#34;buy&#34; rating and issued a $74.00 target price (up from $70.00) on shares of Harrow in a report on Wednesday, October 1st. Cantor Fitzgerald  reiterated an &#34;overweight&#34; rating and issued a $94.00 price objective on shares of Harrow in a research report on Tuesday, November 11th. Zacks Research downgraded Harrow from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Friday, September 12th. HC Wainwright increased their price target on Harrow from $64.00 to $69.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, November 12th. Finally, Craig Hallum boosted their price objective on shares of Harrow from $54.00 to $64.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, September 23rd. Eight investment analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has assigned  a Sell rating to the company's stock. Based on data from MarketBeat.com, Harrow currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $71.43.</p><p><b>Get Our Latest Research Report on HROW</b></p><h2>Harrow Company Profile</h2> (Free Report)<p>Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business.  The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.</p><h2>See Also</h2><ul><li>Five stocks we like better than Harrow</li><li>Why Are Stock Sectors Important to Successful Investing?</li><li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li><li>Earnings Per Share Calculator: How to Calculate EPS</li><li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li><li>How to trade penny stocks: A step-by-step guide</li><li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFJPVw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFJPVw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Harrow Right Now?</h2><p>Before you consider Harrow, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.</p><p>While Harrow currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

HROW

<p>Marshall Wace LLP increased its stake in Harrow, Inc. by 31.5% in Q2, now owning 564,876 shares worth $17.25 million. Harrow's stock is 72.76% owned by institutional investors. The company reported Q3 earnings of $0.33 per share, beating estimates. Analysts have mixed ratings, with a consensus target price of $71.43. Harrow focuses on ophthalmic healthcare and operates ImprimisRx.</p>

Harrow, Inc. $HROW Shares Bought by Marshall Wace LLP